Payment overview · 2025
General Payments
$436.78
24 reported records · 10 companies
Healthcare provider profile · identity verified
Bryan Sean Smithson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHOW LOW, AZ · NPI 1336377464
Verified facts
What the public records show
CMS Open Payments records show Bryan Sean Smithson, MD received $436.78 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.14 | 23.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.22 | 22.3% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.67 | 13.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.91 | 9.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.54 | 7.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.74 | 6.3% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.62 | 6.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.33 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.66 | 3.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.95 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $436.78 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.48 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.48 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.67 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.55 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.55 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.67 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.54 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 99 |
| Lisinopril | Lisinopril | 259 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 62 |
| Losartan Potassium | Losartan Potassium | 218 | 61 |
| Omeprazole | Omeprazole | 166 | 45 |
| Montelukast Sodium | Montelukast Sodium | 154 | 47 |
| Gabapentin | Gabapentin | 148 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 36 |
| Metformin Hcl | Metformin Hcl | 118 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 37 |
| Metformin Hcl Er | Metformin Hcl | 112 | 38 |
| Ozempic | Semaglutide | 107 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 34 |
| Eliquis | Apixaban | 105 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 28 |
| Furosemide | Furosemide | 96 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 36 |
| Famotidine | Famotidine | 90 | 29 |
| Morphine Sulfate Er | Morphine Sulfate | 88 | 13 |
| Trazodone Hcl | Trazodone Hcl | 85 | 21 |
| Allopurinol | Allopurinol | 75 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 11 |
| Potassium Chloride | Potassium Chloride | 74 | 24 |
| Meloxicam | Meloxicam | 70 | 21 |
| Celecoxib | Celecoxib | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 20 |
| Tramadol Hcl | Tramadol Hcl | 66 | 27 |
| Carvedilol | Carvedilol | 64 | 21 |
| Lorazepam | Lorazepam | 63 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 13 |
| Pregabalin | Pregabalin | 53 | 12 |
| Bupropion Xl | Bupropion Hcl | 52 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 16 |
| Glipizide | Glipizide | 44 | 12 |
| Prednisone | Prednisone | 43 | 34 |
| Methocarbamol | Methocarbamol | 40 | 14 |
| Jardiance | Empagliflozin | 38 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Estradiol | Estradiol | 33 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Finasteride | Finasteride | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 13 |
| Azithromycin | Azithromycin | 30 | 29 |
| Ondansetron Odt | Ondansetron | 30 | 21 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | 13 |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Progesterone | Progesterone, Micronized | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 11 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Fentanyl | Fentanyl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Nyamyc | Nystatin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $436.78 · 24 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, NURTEC ODT, Omnipod, Ozempic, PENBRAYA, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, TRUMENBA, Veozah, Wegovy, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error